BRAFV600E mutations occur in ∼10% of colorectal cancer cases, are associated with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT colorectal cancer. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n = 31; validation set: n = 26) colorectal cancer, and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT colorectal cancer subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and UPR pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT colorectal cancer cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis, and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT colorectal cancer. Mol Cancer Ther; 17(6); 1280-90. ©2018 AACR.

Almac Discovery Laboratories Centre for Precision Therapeutics Belfast United Kingdom

Department of Oncology University of Torino School of Medicine Candiolo Torino Italy Candiolo Cancer Institute FPO IRCCS Candiolo Torino Italy

Division of Biomedical Informatics Sidra Medical and Research Center Education City North Campus Doha Qatar

Drug Resistance Group Centre for Cancer Research and Cell Biology School of Medicine Dentistry and Biomedical Science Queen's University Belfast Belfast United Kingdom

Research Centre for Toxic Compounds in the Environment Faculty of Science Masarykova Univerzita Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc19028545

003      

CZ-PrNML

005      

20190823131639.0

007      

ta

008      

190813s2018 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1158/1535-7163.MCT-17-0603 $2 doi

035    __

$a (PubMed)29483217

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Forsythe, Nicholas $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

245    14

$a The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer / $c N. Forsythe, A. Refaat, A. Javadi, H. Khawaja, JA. Weir, H. Emam, WL. Allen, F. Burkamp, V. Popovici, PV. Jithesh, C. Isella, MJ. Labonte, IG. Mills, PG. Johnston, S. Van Schaeybroeck,

520    9_

$a BRAFV600E mutations occur in ∼10% of colorectal cancer cases, are associated with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT colorectal cancer. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n = 31; validation set: n = 26) colorectal cancer, and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT colorectal cancer subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and UPR pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT colorectal cancer cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis, and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT colorectal cancer. Mol Cancer Ther; 17(6); 1280-90. ©2018 AACR.

650    _2

$a antitumorózní látky $x farmakologie $7 D000970

650    _2

$a apoptóza $x účinky léků $x genetika $7 D017209

650    _2

$a nádorové biomarkery $7 D014408

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a viabilita buněk $x účinky léků $x genetika $7 D002470

650    _2

$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x mortalita $7 D015179

650    _2

$a stres endoplazmatického retikula $x účinky léků $x genetika $7 D059865

650    _2

$a proteiny tepelného šoku $x genetika $x metabolismus $7 D006360

650    _2

$a lidé $7 D006801

650    _2

$a kyseliny hydroxamové $x farmakologie $7 D006877

650    _2

$a MAP kinasový signální systém $7 D020935

650    _2

$a biologické modely $7 D008954

650    12

$a mutace $7 D009154

650    _2

$a oligopeptidy $x farmakologie $7 D009842

650    _2

$a prognóza $7 D011379

650    _2

$a proteosyntéza $7 D014176

650    _2

$a inhibitory proteinkinas $x farmakologie $7 D047428

650    _2

$a protoonkogenní proteiny B-raf $x antagonisté a inhibitory $x genetika $x metabolismus $7 D048493

650    _2

$a pyrimidiny $x farmakologie $7 D011743

650    _2

$a signální transdukce $x účinky léků $7 D015398

650    _2

$a transkripční faktor CHOP $x genetika $x metabolismus $7 D051742

650    _2

$a signální dráha UPR $x účinky léků $7 D056811

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Refaat, Alaa $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Javadi, Arman $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Khawaja, Hajrah $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Weir, Jessica-Anne $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Emam, Heba $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Allen, Wendy L $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Burkamp, Frank $u Almac Discovery Laboratories, Centre for Precision Therapeutics, Belfast, United Kingdom.

700    1_

$a Popovici, Vlad $u Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, Czech Republic.

700    1_

$a Jithesh, Puthen V $u Division of Biomedical Informatics, Sidra Medical and Research Center, Education City North Campus, Doha, Qatar.

700    1_

$a Isella, Claudio $u Department of Oncology, University of Torino School of Medicine, Candiolo, Torino, Italy. Candiolo Cancer Institute-FPO IRCCS, Candiolo, Torino, Italy.

700    1_

$a Labonte, Melissa J $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Mills, Ian G $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Johnston, Patrick G $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.

700    1_

$a Van Schaeybroeck, Sandra $u Drug Resistance Group, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom. s.vanschaeybroeck@qub.ac.uk.

773    0_

$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 17, č. 6 (2018), s. 1280-1290

856    41

$u https://pubmed.ncbi.nlm.nih.gov/29483217 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20190813 $b ABA008

991    __

$a 20190823131853 $b ABA008

999    __

$a ok $b bmc $g 1433694 $s 1067005

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 17 $c 6 $d 1280-1290 $e 20180226 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616

GRA    __

$a C212/A13721 $p Cancer Research UK $2 United Kingdom

GRA    __

$a C13749/A13172 $p Cancer Research UK $2 United Kingdom

LZP    __

$a Pubmed-20190813